Dok7 Congenital Myasthenic Syndrome: Case Series and Review of Literature Publisher Pubmed



Ziaadini B¹ ; Ghaderi Yazdi B^{2, 3} ; Dirandeh E⁴ ; Boostani R⁵ ; Karimi N⁶ ; Panahi A^{2, 3} ; Kariminejad A⁷ ; Fadaee M⁷ ; Ahangari F⁷ ; Nafissi S^{2, 3} Show Affiliations
Source: BMC Neurology Published:2024

Abstract

Background: Congenital myasthenic syndromes (CMS) are among the most challenging differential diagnoses in the neuromuscular domain, consisting of diverse genotypes and phenotypes. A mutation in the Docking Protein 7 (Dok-7) is a common cause of CMS. DOK7 CMS requires different treatment than other CMS types. Regarding DOK7’s special considerations and challenges ahead of neurologists, we describe seven DOK7 patients and evaluate their response to treatment. Methods: The authors visited these patients in the neuromuscular clinics of Tehran and Kerman Universities of Medical Sciences Hospitals. They diagnosed these patients based on clinical findings and neurophysiological studies, which Whole Exome Sequencing confirmed. For each patient, we tried unique medications and recorded the clinical response. Results: The symptoms started from birth to as late as the age of 33, with the mean age of onset being 12.5. Common symptoms were: Limb-girdle weakness in 6, fluctuating symptoms in 5, ptosis in 4, bifacial weakness in 3, reduced extraocular movement in 3, bulbar symptoms in 2 and dyspnea in 2 3-Hz RNS was decremental in 5 out of 6 patients. Salbutamol was the most effective. c.1124_1127dupTGCC is the most common variant; three patients had this variant. Conclusion: We strongly recommend that neurologists consider CMS in patients with these symptoms and a similar familial history. We recommend prescribing salbutamol as the first-choice treatment option for DOK7 patients. © The Author(s) 2024.